NCT01631201View on ClinicalTrials.gov

Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

April 30, 2013

Conditions
Chlamydia Trachomatis Infection
Interventions
DRUG

Rifalazil 25 milligram

Single dose of 25 milligram rifalazil to be administered on Day 1.

DRUG

Azithromycin 1 gram

Single dose of Azithromycin 1 gram to be administered on Day 1.

Trial Locations (5)

23456

Research Site, Virginia Beach

35294

Research Site, Birmingham

46202

Research Site, Indianapolis

89106

Research Site, Las Vegas

92108

Research Site, San Diego

All Listed Sponsors
lead

ActivBiotics Pharma, LLC

INDUSTRY

NCT01631201 - Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women | Biotech Hunter | Biotech Hunter